Insmed (INSM) Misses Q4 EPS by 17c; Offers FY23 ARIKAYCE Revenue Guidance
Tweet
Share
E-mailGet Alerts INSM Hot Sheet
Price: $120.00 -3.21%
EPS Growth %: +78.3%
Financial Fact:
Income tax expense: 25K
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +78.3%
Financial Fact:
Income tax expense: 25K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Insmed (NASDAQ: INSM) reported Q4 EPS of ($1.21), $0.17 worse than the analyst estimate of ($1.04). Revenue for the quarter came in at $59.3 million versus the consensus estimate of $63.57 million.
Insmed continues to expect full-year 2023 global revenues for ARIKAYCE to be between $285 million and $300 million.
For earnings history and earnings-related data on Insmed (INSM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Arrive AI and DXC Technology partner to bring delivery tech to factories
- Corpay agrees to $100M FTC settlement over marketing practices
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
